Ironwood Pharmaceuticals, Inc. to Post Q1 2024 Earnings of $0.14 Per Share, Capital One Financial Forecasts (NASDAQ:IRWD)

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Research analysts at Capital One Financial issued their Q1 2024 EPS estimates for shares of Ironwood Pharmaceuticals in a research note issued on Wednesday, May 1st. Capital One Financial analyst T. Chiang expects that the biotechnology company will post earnings of $0.14 per share for the quarter. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.71 per share. Capital One Financial also issued estimates for Ironwood Pharmaceuticals’ Q2 2024 earnings at $0.17 EPS, Q3 2024 earnings at $0.18 EPS, Q4 2024 earnings at $0.18 EPS and FY2026 earnings at $1.03 EPS.

IRWD has been the topic of several other research reports. Piper Sandler boosted their price target on shares of Ironwood Pharmaceuticals from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. Craig Hallum assumed coverage on shares of Ironwood Pharmaceuticals in a research note on Wednesday, January 17th. They issued a “buy” rating and a $21.00 price target on the stock. Wells Fargo & Company decreased their price target on shares of Ironwood Pharmaceuticals from $20.00 to $14.00 and set an “overweight” rating on the stock in a research note on Friday, March 1st. Finally, StockNews.com cut shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, April 6th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, Ironwood Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $19.80.

Ironwood Pharmaceuticals Stock Up 1.0 %

Shares of IRWD stock opened at $8.30 on Thursday. The stock has a market cap of $1.30 billion, a P/E ratio of -1.27 and a beta of 0.57. Ironwood Pharmaceuticals has a 52 week low of $7.53 and a 52 week high of $15.70. The company’s fifty day simple moving average is $8.96 and its two-hundred day simple moving average is $10.61.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in IRWD. Xponance Inc. bought a new position in Ironwood Pharmaceuticals during the 3rd quarter valued at about $144,000. GW Henssler & Associates Ltd. bought a new position in Ironwood Pharmaceuticals in the 3rd quarter worth about $186,000. Mackenzie Financial Corp grew its stake in Ironwood Pharmaceuticals by 21.5% in the 3rd quarter. Mackenzie Financial Corp now owns 12,713 shares of the biotechnology company’s stock worth $123,000 after acquiring an additional 2,253 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Ironwood Pharmaceuticals by 3.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 91,060 shares of the biotechnology company’s stock worth $877,000 after acquiring an additional 3,460 shares in the last quarter. Finally, Inspire Investing LLC grew its stake in Ironwood Pharmaceuticals by 7.8% in the 3rd quarter. Inspire Investing LLC now owns 31,669 shares of the biotechnology company’s stock worth $305,000 after acquiring an additional 2,294 shares in the last quarter.

Insider Transactions at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, Director Jon R. Duane bought 6,920 shares of Ironwood Pharmaceuticals stock in a transaction dated Wednesday, March 6th. The shares were purchased at an average cost of $8.70 per share, for a total transaction of $60,204.00. Following the acquisition, the director now directly owns 121,028 shares in the company, valued at approximately $1,052,943.60. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, Director Jon R. Duane purchased 6,920 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The shares were bought at an average cost of $8.70 per share, for a total transaction of $60,204.00. Following the acquisition, the director now owns 121,028 shares of the company’s stock, valued at approximately $1,052,943.60. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Thomas A. Mccourt sold 177,164 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $15.24, for a total transaction of $2,699,979.36. Following the transaction, the chief executive officer now owns 832,774 shares in the company, valued at $12,691,475.76. The disclosure for this sale can be found here. Insiders have sold a total of 273,008 shares of company stock worth $4,160,642 in the last three months. Insiders own 13.10% of the company’s stock.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.